VolitionRx Partners with Fujifilm to Launch Feline Cancer Test Nu.Q® Vet in Japan

VolitionRx and Fujifilm: A Groundbreaking Partnership for Feline Health



In an exciting move for pet health, VolitionRx Limited, a multi-national epigenetics company, has announced the expansion of its supply agreement with Fujifilm Vet Systems in Japan. This partnership aims to roll out the Nu.Q® Vet Feline Test, poised to become the world's first straightforward and cost-effective blood-based liquid biopsy test designed specifically for detecting cancer in cats.

Livestock statistics indicate that there are approximately nine million cats in Japan, making the potential market for this innovative diagnostic tool vast and promising. Although cats are beloved companions to many, the veterinary community has faced significant challenges in diagnosing cancer early due to the lack of reliable tumor biomarkers. The Nu.Q® Vet technology has the potential to transform this landscape, addressing a critical unmet need in feline oncology.

Junichi Makino, President and Representative Director at Fujifilm Vet Systems, expressed enthusiasm for the partnership, emphasizing the importance of this diagnostic tool. "Feline oncology lacks tumor biomarkers, and so cancer in cats has been notoriously difficult to diagnose early," he stated. The Nu.Q® Vet Canine Test, which launched in July 2024, garnered significant interest from Japanese veterinarians, prompting the introduction of an automated testing option to expedite results. The compelling accuracy of preliminary assays for detecting lymphoma, the most prevalent cancer type in cats, has contributed to this optimism.

Dr. Jasmine Kway, CEO of Volition Singapore, highlighted how this collaboration with Fujifilm could open up lucrative revenue opportunities for VolitionRx within the burgeoning feline health market. With one in five cats expected to face a cancer diagnosis at some point in their lives, the ability to detect these diseases earlier stands to significantly improve outcomes for affected pets.

It is increasingly recognized that pet ownership is on the rise worldwide, with an estimated one billion cats and dogs living globally. The surge in pet ownership, particularly in emerging economies, reinforces the pressing need for accessible health care solutions for pets. The mission of VolitionRx is straightforward: integrate cancer screening into every pet's routine wellness check. Following the recent success of their canine cancer test, this next step into feline diagnostics represents a pivotal moment in veterinary medicine.

The anticipated Nu.Q® Vet Feline Test promises to not only enhance the diagnostic toolkit available to veterinarians but also aims to make significant advances in early cancer detection for cats — a goal that can lead to earlier interventions and better management of diseases. As the product development progresses and the Nu.Q® Vet Feline Test prepares for launch on the IDS i10® automated analyzer platform, stakeholders are eagerly watching for further developments.

With adept collaborations and pioneering technology, VolitionRx is positioned to make sizable impacts in both pet health and the broader field of veterinary diagnostics. Their innovative approach offers new hope for better management of feline health and may well redefine how veterinarians approach cancer detection in pets. The future looks brighter not just for cat owners, but for the veterinary professionals dedicated to ensuring the health and well-being of these cherished animals.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.